Skip to main content
OpenTrials
Completed

NCT Number: NCT02974309

Family Routines Enhancing Adolescent Diabetes by Optimizing Management

A three month randomized study to examine the potential benefits of sleep extension in tandem with clinical trial on diabetes management in youth with type 1 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pediatric Endocrinology Clinic

Tucson, Arizona, 85719, United States

About this study

Type 1 Diabetes (T1DM) is one of the most common chronic medical conditions that occur in children. More than two-thirds of these young patients struggle to maintain optimal glycemic control. On a seemingly unrelated front, insufficient sleep has become a public health crisis as less than 30% of youth achieve the recommended number of hours on school nights. Prior research has supported that sleep disturbances contribute to elevated glucose levels and have a significant impact on memory, attention, and planning. These skills are essential to effective diabetes management. Despite the link between sleep and diabetes, no research has examined the benefits of an intervention to help these youth achieve a healthy sleep duration. To that end, our primary objective is to determine the effect of sleep extension on glycemic control and psychosocial functioning. Our secondary objective is to determine mediators and moderators of effect. The central hypothesis is that an increase in sleep duration will lower glucose levels and improve behavioral ratings (internalizing, externalizing, and classroom behaviors). Our primary study aims are to (1) Test if lengthening sleep improves glycemic control and psychosocial function in youth with T1DM; (2) Assess putative mechanisms for the effects of sleep extension on glucose and psychosocial function; and (3) Examine the possible moderating effect of pre-existing sleep parameters and sociodemographic variables that modify the impact of sleep extension. A secondary aim is exploratory to examine additional pre-selected mediators and moderators. In the proposed randomized study, up to 175 youth with T1DM will be assigned to a Sleep Extension or a supportive routines condition. The Sleep Extension lengthens youth's time in bed to allow for a healthy sleep duration on a consistent basis, whereas the supportive routines condition reinforces daytime and nighttime activities. We will test the impact of sleep extension on key indices of glycemic control (average glucose levels and % time hyperglycemia using continuous glucose monitors and HbA1C) as well as putative mechanisms of effect (e.g., heart rate variability and salivary cortisol levels) and participant characteristics that might mitigate the benefits of sleep extension (e.g., sleep-disordered breathing, adherence, and SES). Once our aims are achieved and a causal link is established, the proposed Sleep Extension intervention will advance knowledge about the role of sleep in diabetes management and provide a beneficial intervention to help youth with T1DM.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 1 diabetes

Exclusion criteria

  • neurological, developmental, or psychiatric condition that in the opinion of the PI would significantly interfere with sleep or participation
  • not hospitalized within the previous month prior to enrollment

Treatment and study plan

Sleep Extension

Behavioral

All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer

Routine

Behavioral

All youth in this condition are asked to follow the routines set by their clinical care team.

Primary outcomes

  1. HbA1c

    Time frame: 3 months

    A measure of glucose control

Secondary outcomes

  1. Glucose Levels via continuous glucose monitor

    Time frame: 1 and 3 months

    Glucose levels will be measured at regular intervals using a subcutaneous continuous glucose monitor

  2. Sleep Duration

    Time frame: 3 months

    Sleep duration will be measured using a combination of wrist actigraphy and polysomnography data.

Other outcomes

  1. Diabetes Self-Management

    Time frame: 1 and 3 months

    Diabetes self-management and care activities will be assessed using the Diabetes Self-Management Profile for Flexible Regimes, Self- and Parent-proxy reports

  2. Adherence to Diabetes Management

    Time frame: 1 and 3 months

    Adherence to diabetes management will be measured using the average daily manual glucose measurements from a personal glucometer (i.e. finger sticks)

  3. Polysomnographic Sleep Architecture

    Time frame: 1 and 3 months

    Sleep architecture will be measured as percent time spent sleeping in the different stages of sleep (NREM 1, 2, 3, REM) using an in-home polysomnography system.

  4. Quality of Life

    Time frame: 1 and 3 months

    Quality of Life will be measured using an aggregate of the Pediatric Quality of Life Inventory (PedsQL) Core 4.0 and Diabetes 3.2 modules.

  5. Cortisol

    Time frame: 1 and 3 months

    Morning and evening Cortisol levels will be measured using a saliva collection device

Sponsors and collaborators

Lead sponsor

University of Arizona

Other

Registry information

Official study title

Extending Sleep to Improve Glycemic Control in Pediatric Type 1 Diabetes

Acronym: FREADOM

Important dates

Study start
2017
Primary completion
2024
Study completion
2024
First posted
Nov 28, 2016
Registry last updated
Nov 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.